# US 2021/0060067 A1 · Enhanced immune cells using dual shrna and composition including the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060067 A1
- Document ID: US20210060067A1
- Status: Published application
- Kind: A1
- Application number: 16/958,649
- Filed: 2019-01-10
- Published: 2021-03-04
- Earliest claimed: 2018-01-12
- Assignees: Curocell Inc.; Korea Advanced Institute of Science and Technology
- Applicants: Curocell Inc.; Korea Advanced Institute of Science and Technology
- Inventors: Chan Hyuk KIM; Young-Ho LEE; Yujean LEE; HyeongJi LEE; Sang Hoon LEE
- Web page: https://patentgrep.com/patent/US20210060067A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/36: Immune checkpoint inhibitors
- A61K 40/4211: {CD19 or B4}
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2818: {against CD28 or CD152}
- C12N 5/0636: {T lymphocytes}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/1075: {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/31: multispecific
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/70: characterized by effect upon binding to a cell or to an antigen
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/715: containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
- C12N 2310/122: Hairpin
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/31: Combination therapy
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/51: Specially adapted vectors
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present invention generally relates to an immune cell comprising a genetically engineered antigen receptor that specifically binds to a target antigen and a genetic disruption agent that reduces or is capable of reducing the expression in the immune cell of a gene that weakens the function of the immune cell.

## Claims

### Claim at position 1

-149. (canceled)

### Claim 150

A method of treating cancer, comprising administering an immune cell to a human subject having cancer, said immune cell comprising (i) a first nucleotide sequence encoding a first short hairpin RNA (shRNA) that inhibits expression of Programmed Cell Death 1 (PD-1) and a second shRNA that inhibits expression of T cell immunoreceptor with Ig and ITIM domains (TIGIT), and (ii) a second nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular antigen recognition domain that binds a target antigen associated with the cancer, a transmembrane domain, and an intracellular signal transduction domain.

### Claim 151 (depends on 150)

The method of claim 150, wherein the target antigen is a cancer antigen whose expression is increased in or on the surface of a cancer cell, a cancer tissue, and/or a tumor microenvironment.

### Claim 152 (depends on 150)

The method of claim 150, wherein the target antigen is CD19 or CD22.

### Claim 153 (depends on 150)

The method of claim 150, wherein the immune cell is a human-derived T cell, a dendritic cell or natural killer (NK) cell.

### Claim 154 (depends on 150)

The method of claim 150, wherein the immune cell is a human-derived T cell.

### Claim 155 (depends on 150)

The method of claim 150, wherein the intracellular signal transduction domain of the CAR further comprises a costimulatory molecule selected from the group consisting of ICOS, OX40, CD137 (4-1BB), CD27, and CD28.

### Claim 156 (depends on 150)

The method of claim 150, wherein the first nucleotide sequence is present on a vector.

### Claim 157 (depends on 150)

The method of claim 150, wherein the first nucleotide sequence and the second nucleotide sequence are present on a single vector.

### Claim 158

A vector comprising (i) a first nucleotide sequence encoding a first shRNA that inhibits expression of Programmed Cell Death 1 (PD-1) and a second shRNA that inhibits expression of T cell immunoreceptor with Ig and ITIM domains (TIGIT), and (ii) a second nucleotide sequence encoding a CAR.

### Claim 159 (depends on 158)

The vector of claim 158, wherein the expression of the first shRNA is regulated by a first promoter and the second shRNA is regulated by a second promoter.

### Claim 160 (depends on 159)

The vector of claim 159, wherein the first and the second promoters are RNA polymerase III promoters.

### Claim 161 (depends on 160)

The vector of claim 160, wherein the RNA polymerase III promoters are U6 promoters.

### Claim 162 (depends on 159)

The vector of claim 159, wherein the two promoters are oriented in different directions from each other on the vector.

### Claim 163 (depends on 162)

The vector of claim 162, wherein the two promoters are oriented in head to head orientation.

### Claim 164 (depends on 162)

The vector of claim 162, wherein the two promoters are oriented in tail to tail orientation.

### Claim 165 (depends on 158)

An immune cell comprising the vector of claim 158.

### Claim 166 (depends on 165)

A pharmaceutical composition comprising the immune cell of claim 165 and a pharmaceutically acceptable carrier.
